ClinicalTrials.gg
RecruitingNCT07263594Updated May 22, 2026

A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

A Phase 1/2 interventional study of DB-1324 in Gastrointestinal Cancer, sponsored by DualityBio Inc.. Recruiting at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by DualityBio Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
73rd of 245
127 · median 60
Started
2026
with 15 others
Phase 1/2
40 of 316
14 open now
Primary completion
2028-12
later than 92 of 113 live
Registered
302nd of 316
by date

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 73rd largest by planned enrollment of the 245 interventional ones that give a count, is one of 16 that started in 2026, is one of 40 in phase 1/2, reaches primary completion later than 92 of the 113 other live ones, and was the 302nd registered.

Gastrointestinal Neoplasms

696 studies on the registry are indexed under Gastrointestinal Neoplasms; 209 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.

Read the detailed description

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2 study to explore the safety, tolerability, and efficacy of DB-1324 in participants with malignant GI tumors.

The Phase 1, which includes Dose Escalation, Backfill, and Dose Expansion to identify the MTD and determine the RDEs and RP2D.

Phase 2 will confirm the safety, tolerability, and explore efficacy in selected malignant GI tumors.

For both Phase 1 and Phase 2, participants will receive study treatment until 1) disease progression, 2) loss of clinical benefit in the opinion of the investigator, 3) unacceptable toxicity, 4) withdrawal from study treatment by participant, 5) lost to follow up, or 6) another criterion for discontinuation is met, whichever occurs first.

03

Conditions studied

  • Gastrointestinal Cancer

Keywords

  • Gastrointestinal Tumors, DB-1324
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. documented advanced/unresectable, or GI tumor.
  2. Have or progressed on or after standard systemic treatments, or are intolerant to standard treatment, or for which no standard treatment is available.
  3. At least one as assessed by the investigator according to response evaluation criteria in v1.1.
  4. Has a of ≥ 3 months.
  5. Has an PS of 0-1.
  6. Has ≥ 50% by either ECHO or MUGA within 28 days before enrollment.
  7. Has adequate organ functions within 7 days prior to Day 1 of Cycle 1.
  8. Has an adequate treatment before Day 1 of Cycle 1.
  9. Participants are willing to provide archived tumor tissue or undergo a tumor for the measurement of CDH17 levels and other biomarkers.
  10. Other protocol-defined Inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with CDH17 targeted therapy.
  2. Prior treatment with ADC with topoisomerase I inhibitor.
  3. Has chronic enteritis or inflammatory bowel disease. Or has bleeding of GI tract or adjacent organs within 1 month prior to the first dose of study treatment. Or has clinically significant obstruction and/or perforation and/or fistulae (including prior GI fistula operation) of GI tract or adjacent tissues within 6 months prior to the first dose of study treatment.
  4. Uncontrolled or significant cardiovascular disease.
  5. Has a medical history of cerebrovascular accident including within 6 months before enrollment.
  6. Has a history of (non-infectious) ILD/pneumonitis that required , or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  7. Have a lung-specific intercurrent clinically significant illness.
  8. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.
  9. Has clinically active .
  10. Has unresolved toxicities from previous anticancer therapy.
  11. Other protocol-defined Exclusion criteria apply.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
127 participants (estimated)

Study arms

  • Experimental
    DB-1324 Phase 1 Dose escalation

    Enrolled Subjects will receive a single-dose of DB-1324 at different Dose Level or different dose regimen

    Drug: DB-1324

  • Experimental
    DB-1324 Phase 1 Backfill

    Participants with GI cancers who have received no more than 3 prior lines of systemic therapy may be backfilled at the selected dose regimens to further explore the safety, efficacy, PK, and pharmacodynamics of DB-1324.

    Drug: DB-1324

  • Experimental
    DB-1324 Phase 1 Dose Expansion

    Two or more appropriate dose regimens of DB-1324, determined from the emerging dose escalation (and backfill) data, will be explored for preliminary efficacy and safety of DB-1324.

    Drug: DB-1324

  • Experimental
    DB-1324 Phase 2

    Phase 2 will consist of one or more cohorts intended to confirm early signals of efficacy identified in Phase 1.

    Drug: DB-1324

Interventions

  • DrugDB-1324

    Administered I.V.

06

What researchers measure

Primary outcomes

  1. Dose Escalation and Backfill parts: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0.

    Percentage of participants in dose escalation and backfill parts with DLTs

    Time frame: Up to safety follow-up visit, approximately 30 days post-treatment

  2. Dose Escalation and Backfill parts: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.

    Percentage of participants with SAEs in dose escalation and backfill parts graded according to NCI CTCAE v5.0

    Time frame: Up to safety follow-up visit, approximately 30 days post-treatment

  3. Dose Escalation and Backfill parts: Percentage of participants with Treatment Emergent Adverse Events (TEAEs) , Grade ≥ 3 TEAE, TEAE leading to dose reduction/interruption/discontinuation

    Percentage of participants who experienced any of the above TEAEs in dose escalation and backfill parts graded according to NCI CTCAE v5.0

    Time frame: Up to safety follow-up visit, approximately 30 days post-treatment

  4. Dose Escalation and Backfill parts: Maximum Tolerated Dose(MTD) of DB-1324

    MTD will be determined by evaluating the incidence of DLTs during the DLT assessment period.

    Time frame: Up to safety follow-up visit, approximately 30 days post-treatment

Secondary outcomes

  1. Dose Escalation and Backfill parts: Recommended Dose for Expansions(RDEs)

    RDEs will be based on the data collected during dose escalation and backfill parts

    Time frame: Up to the completion of Phase 1, assessed up to 12 months

  2. Dose Escalation, Backfill and Expansion parts: Recommended Phase 2 Dose(RP2D)

    RP2D will be based on the data collected during dose escalation, backfill and expansion parts

    Time frame: From the beginning of first patient in (FPI) to the end of study, approximately 36 months

  3. Dose Escalation and Backfill parts: Objective Response Rate (ORR)

    ORR will be determined by investigator per RECIST v1.1, defined as the percentage of participants who had a best response rating of CR and PR

    Time frame: From the beginning of first patient in (FPI) to the end of study, approximately 36 months

  4. Dose Escalation and Backfill parts: Duration of Response (DoR)

    DoR will be determined by investigator per RECIST v1.1, defined as the time from earliest date of documented CR or PR to the date of documented disease progression or death (by any cause, in the absence of progression)

    Time frame: From the beginning of first patient in (FPI) to the end of study, approximately 36 months

  5. Dose Escalation and Backfill parts: Disease Control Rate (DCR)

    DCR will be determined by investigator per RECIST v1.1, defined as the proportion of participants with best overall response of CR, PR, or SD with confirmation over a period of at least 6 weeks.

    Time frame: From the beginning of first patient in (FPI) to the end of study, approximately 36 months

  6. Dose Escalation and Backfill parts: Time to Response (TTR)

    TTR will be determined by investigator per RECIST v1.1, defined as the time from the first administration to first documented CR or PR.

    Time frame: From the beginning of first patient in (FPI) to the end of study, approximately 36 months

  7. Dose Escalation and Backfill parts: Progression Free Survival (PFS)

    PFS will be determined by investigator per RECIST v1.1, defined as the time from the first administration to documented disease progression or death (by any cause, in the absence of progression), whichever occurs first.

    Time frame: From the beginning of first patient in (FPI) to the end of study, approximately 36 months

  8. Dose Escalation and Backfill parts: Pharmacokinetic-AUClast

    Area under the concentration-time curve from time 0 to the last of DB-1324, total anti-CDH17 antibody, and unconjugated payload.

    Time frame: Up to safety follow up visit, approx. 30 days post-treatment

  9. Dose Escalation and Backfill parts: Pharmacokinetic-AUC0-τ

    Area under the concentration-time curve from time 0 to time tau of DB-1324, total anti-CDH17 antibody, and unconjugated payload.

    Time frame: Up to safety follow up visit, approx. 30 days post-treatment

  10. Dose Escalation and Backfill parts: Pharmacokinetic-Cmax

    Maximum observed plasma concentration (Cmax) of DB-1324, total anti-CDH17 antibody, and unconjugated payload.

    Time frame: Up to safety follow up visit, approx. 30 days post-treatment

  11. Dose Escalation and Backfill parts: Pharmacokinetic-Tmax

    Time to Cmax of DB-1324, total anti-CDH17 antibody, and unconjugated payload.

    Time frame: Up to safety follow up visit, approx. 30 days post-treatment

  12. Dose Escalation and Backfill parts: Pharmacokinetic-Cthroug

    Trough concentration

    Time frame: Up to safety follow up visit, approx. 30 days post-treatment

  13. Dose Escalation and Backfill parts: Anti-drug antibody (ADA) prevalence

    Percentage of participants who are ADA positive at any point

    Time frame: Up to safety follow up visit, approx. 30 days post-treatment

07

Study locations

9 of 9 sites recruiting
  • USA05-0
    Port Saint Lucie, Florida 34952, United States
    Recruiting
  • USA02-0
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • USA01-0
    Huntersville, North Carolina 28078, United States
    Recruiting
  • USA03-0
    Cincinnati, Ohio 45219, United States
    Recruiting
  • AUS02-0
    Randwick, New South Wales 2031, Australia
    Recruiting
  • AUS03-0
    South Brisbane, Queensland 4101, Australia
    Recruiting
  • AUS01-0
    Nedlands, Western Australia 6009, Australia
    Recruiting
  • CHN01-0
    Beijing, 100142, China
    Recruiting
  • CHN04-0
    Beijing, 102206, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

Of 36 phase 1/2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 4, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07263594
Lead sponsor
DualityBio Inc.
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Jan 20, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 22, 2026

Study contacts

Zhaochuan Wang
Contact
zhaochuan.wang@dualitybiologics.com
4123279868
Lily Hu
study director · DualityBio Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion